BrainStorm Eyes New Phase III Trial For NurOwn In Mild ALS Following BLA Withdrawal

 
• By Sue Sutter
Line not crossed
NurOwn shows there is a line that FDA will not cross when it comes to regulatory flexibility. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet